These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25085000)

  • 1. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer.
    Idorn M; Køllgaard T; Kongsted P; Sengeløv L; Thor Straten P
    Cancer Immunol Immunother; 2014 Nov; 63(11):1177-87. PubMed ID: 25085000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
    Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
    Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased circulating polymorphonuclear myeloid-derived suppressor cells are associated with prognosis of metastatic castration-resistant prostate cancer.
    Kobayashi T; Nagata M; Hachiya T; Wakita H; Ikehata Y; Takahashi K; China T; Shimizu F; Lu J; Jin Y; Lu Y; Ide H; Horie S
    Front Immunol; 2024; 15():1372771. PubMed ID: 38887300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy.
    Pal S; Nandi M; Dey D; Chakraborty BC; Shil A; Ghosh S; Banerjee S; Santra A; Ahammed SKM; Chowdhury A; Datta S
    Aliment Pharmacol Ther; 2019 May; 49(10):1346-1359. PubMed ID: 30982998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
    Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
    Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Intensification in HIV-Infected Patients Is Associated With Reduced Frequencies of Regulatory T Cells.
    Grützner EM; Hoffmann T; Wolf E; Gersbacher E; Neizert A; Stirner R; Pauli R; Ulmer A; Brust J; Bogner JR; Jaeger H; Draenert R
    Front Immunol; 2018; 9():811. PubMed ID: 29760693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
    Hoechst B; Ormandy LA; Ballmaier M; Lehner F; Krüger C; Manns MP; Greten TF; Korangy F
    Gastroenterology; 2008 Jul; 135(1):234-43. PubMed ID: 18485901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma.
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Van Gele M; van Geel N; Brochez L
    J Transl Med; 2015 Jan; 13():9. PubMed ID: 25592374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
    Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
    J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients.
    Napolitano M; D'Alterio C; Cardone E; Trotta AM; Pecori B; Rega D; Pace U; Scala D; Scognamiglio G; Tatangelo F; Cacciapuoti C; Pacelli R; Delrio P; Scala S
    Oncotarget; 2015 Apr; 6(10):8261-70. PubMed ID: 25823653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yeast-Derived Particulate β-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC Apoptosis and Monocytic MDSC Differentiation to APC in Cancer.
    Albeituni SH; Ding C; Liu M; Hu X; Luo F; Kloecker G; Bousamra M; Zhang HG; Yan J
    J Immunol; 2016 Mar; 196(5):2167-80. PubMed ID: 26810222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells.
    Hock BD; Mackenzie KA; Cross NB; Taylor KG; Currie MJ; Robinson BA; Simcock JW; McKenzie JL
    Nephrol Dial Transplant; 2012 Jan; 27(1):402-10. PubMed ID: 21617199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
    Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
    J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease.
    Kalathil SG; Lugade AA; Pradhan V; Miller A; Parameswaran GI; Sethi S; Thanavala Y
    Am J Respir Crit Care Med; 2014 Jul; 190(1):40-50. PubMed ID: 24825462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocytic myeloid-derived suppressor cells accumulate in renal transplant patients and mediate CD4(+) Foxp3(+) Treg expansion.
    Luan Y; Mosheir E; Menon MC; Wilson D; Woytovich C; Ochando J; Murphy B
    Am J Transplant; 2013 Dec; 13(12):3123-31. PubMed ID: 24103111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies.
    Duffy A; Zhao F; Haile L; Gamrekelashvili J; Fioravanti S; Ma C; Kapanadze T; Compton K; Figg WD; Greten TF
    Cancer Immunol Immunother; 2013 Feb; 62(2):299-307. PubMed ID: 23011590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
    Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
    Weide B; Martens A; Zelba H; Stutz C; Derhovanessian E; Di Giacomo AM; Maio M; Sucker A; Schilling B; Schadendorf D; Büttner P; Garbe C; Pawelec G
    Clin Cancer Res; 2014 Mar; 20(6):1601-9. PubMed ID: 24323899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the clinical significance of lymphocyte subsets and myeloid suppressor cells in patients with renal carcinoma.
    Li Y; Wu Z; Ni C; Li Y; Wang P
    Discov Oncol; 2024 Sep; 15(1):512. PubMed ID: 39347882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
    Meyer C; Cagnon L; Costa-Nunes CM; Baumgaertner P; Montandon N; Leyvraz L; Michielin O; Romano E; Speiser DE
    Cancer Immunol Immunother; 2014 Mar; 63(3):247-57. PubMed ID: 24357148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.